Adults Living with Ulcerated Colitis Will Have Treatment Option of AbbVie’s Anti-TNF Humira

The National Institute for Health and Care Excellence (NICE) announced that AbbVie’s anti-TNF treatment, Humira (adalimumab), is recommended as an option for adults in England living with moderate to severely active ulcerative colitis, who have not adequately responded to conventional therapy. Having additional effective anti-TNF treatment options like adalimumab is important — UC is a debilitating and painful inflammatory bowel condition which can severely impact quality of life, limiting personal freedom and life-chances for the patient.

Dr Neil Pumford, UK Medical Director, AbbVie said: “We welcome the NICE decision as we believe that anti-TNF treatments, such as adalimumab, have an important role to play in the treatment of UC. The evidence supporting the clinical effectiveness of anti-TNFs in reducing the pain and inflammation associated with UC in this patient group is unquestionable. Anti-TNFs may also reduce hospital admissions related to UC 2, helping to give patients much-needed control back over their lives.”